<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908778</url>
  </required_header>
  <id_info>
    <org_study_id>PVD- 302</org_study_id>
    <nct_id>NCT00908778</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects</brief_title>
  <official_title>A Phase 3 Safety and Efficacy Study of Vitreosolve® for Four Ophthalmic Intravitreal Injections For Inducing Posterior Vitreous Detachment in Retinopathy Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vitreoretinal Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vitreoretinal Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of Vitreosolve® in diabetic
      retinopathy patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ultrasound, OCT, and clinical exam</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ultrasound ,OCT ,Safety, and Clinical Exam</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Vitreosolve I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitreosolve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitreosolve</intervention_name>
    <description>intravitreal injection</description>
    <arm_group_label>Vitreosolve I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitreosolve</intervention_name>
    <description>intravitreal injection</description>
    <arm_group_label>Vitreosolve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a history of systemic diabetes(type I,or II)

          -  Subject with a documented history of Non- proliferative Diabetic Retinopathy(NPDR)

          -  Subjects with no or partial PVD at baseline exam in study eye.

        Exclusion Criteria:

          -  Subjects with retinal pathology in the study eye other then (NPDR)

          -  Subjects with high myopia in the study eye

          -  Subjects who have monocular vision or central lateral vision of 20/200 or worse BCVA
             in the non-study eye.

          -  Subjects with an aphakic study eye or if pseudophakic, cataract extraction surgery
             less then 6 months prior to study enrollment.

          -  Subjects that have either vitrectomy surgery, intavitreal injections, or laser
             treatments in the study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo Quiroz-Mercado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APEC, Hospital La Ceguera</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naresh Mandova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip N Calvillo</last_name>
    <phone>949-753-1008</phone>
    <phone_ext>120</phone_ext>
    <email>Philip@vrtco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LVPEI</name>
      <address>
        <city>Vizag</city>
        <state>AP</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amrita</name>
      <address>
        <city>Kochi</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>La Ceguera</name>
      <address>
        <city>San Lucas</city>
        <state>Coyoacan</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Conde De Valenciana</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hidalgo</name>
      <address>
        <city>Monterrey</city>
        <state>Neuvo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <last_update_submitted>October 19, 2009</last_update_submitted>
  <last_update_submitted_qc>October 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hampar Karageozian</name_title>
    <organization>CEO</organization>
  </responsible_party>
  <keyword>Diabetic Retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Vitreous Detachment</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

